Abstract
<title>Abstract</title> Introduction: Central line–associated bloodstream infections (CLABSI) are serious patient safety hazards in pediatric intensive care. Children from hemato-oncology have prolonged line duration yet may incur different infection risks and resistance patterns versus general PICU patients. Thus, the aim of the study was to compare central line utilization, incidence of CLABSI, risk factors and antimicrobial resistance between PICU and hemato-oncology patients, and to identify targets for quality improvement in a resource-limited setting. Methods A prospective observational study in a tertiary PICU in India over 24 months. All children aged 1 month–18 years requiring central venous access were enrolled. We recorded insertion practices, line duration, and CLABSI incidence using standard definitions. Antimicrobial isolates and resistance profiles were compared between the PICU and hemato-oncology subgroups. Results Among 1,931 central line days in 69 children, there were 13 CLABSI episodes. Hemato-oncology patients had longer line durations but lower CLABSI incidence (5.08/1,000 line days) vs general PICU patients (10.87/1,000 line days). Gram-negative bacteria predominated across both groups; PICU isolates showed higher resistance to cephalosporins and carbapenems. Conclusion Infection risk in PICU is shaped not only by line duration but also by insertion urgency, patient acuity, and antimicrobial exposure. Structured bundles, safe insertion/maintenance practices, and stewardship programs are recommended to improve patient safety in pediatric critical care in LMICs.
Affiliated Institutions
Related Publications
CDC Clinical Practice Guideline for Prescribing Opioids for Pain<b>—</b>United States, 2022
This guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years. It updates the CDC Guideline for...
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer
Purpose To compare the effectiveness and tolerability of gemcitabine plus cisplatin with single-agent gemcitabine as first-line chemotherapy for locally advanced or metastatic p...
Gemcitabine Plus<i>nab</i>-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Purpose The trial objectives were to identify the maximum-tolerated dose (MTD) of first-line gemcitabine plus nab-paclitaxel in metastatic pancreatic adenocarcinoma and to provi...
Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies
Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of thera...
Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study
Abstract Objectives To describe the characteristics of children and adolescents affected by an outbreak of Kawasaki-like multisystem inflammatory syndrome and to evaluate a pote...
Publication Info
- Year
- 2025
- Type
- article
- Citations
- 0
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.21203/rs.3.rs-7851349/v1